Introduction {#s1}
============

Currently, tumors are increasingly becoming a global health issue. According to an epidemiological survey, cancer already surpasses cardiovascular and cerebrovascular accidents, and ranks as the top life-threatening disease worldwide. A status report on the global burden of cancer using GLOBOCAN estimated 18.1 million new cancer cases and 9.6 million cancer deaths in 2018 year alone ([@B7]). The overall cancer (containing more than 18 types of cancer) 5-year survival rates in China, Japan, and the United States were 36.0%, 57.4%, and 64.0% ([@B2]), which suggests a significant variation among different countries.

The reasons that make cancer so tough to deal with are complicated. Basically speaking, dysfunctional cell cycle regulation with an excessive proliferation capacity and undifferentiated immature phenotype are the hallmarks of cancer pathology. Besides, tumor cells show intrinsic aberrance of multiple cellular processes. High expression of pro-survival genes like *BCL-2* and *MCL1* render them apoptosis resistant ([@B49]), and metabolic pathways are rewired to make tumor cells better adapt to the changing environment. Tumor cells are experts in nutrient utilization; they adopt distinct metabolic programs, ranging from glycolysis, fatty acid oxidation, to amino acid metabolism under various circumstances. Accompanied by the elevated metabolic activity required for uncontrolled growth, the production of reactive oxygen species (ROS) is substantially increased, which further causes genomic instability and accumulation of genetic mutation ([@B45]). Interestingly, autophagy seems to play a dual role in tumor development. During the early stage, autophagy inhibits tumor formation through alleviating cellular stress; however, this mechanism is then hijacked by later-stage tumor cells to facilitate their growth under extreme conditions. To make things awkward, tumors could also have active impact on the microenvironment where they live. VEGF-C from tumor cells promotes blood and lymphatic vessel neogenesis, which is in favor of tumor cells' development and metastasis ([@B36]). Meantime, immune cells are educated into a tolerant or anergic state, thus leading to tumor immune evasion.

Researches on cancer treatment are focused on two aspects: one is to discover new anti-tumor therapy, while another is to establish an efficient drug-delivery system. With the advance of medical science, we now possess huge artillery of weapons against tumor. Conventional protocols including surgical removal, radio-therapy, and chemotherapy form the basis of clinical therapies. Strikingly, immunological approaches are emerging as a strong supplement. The deployment of cell-based CAR-T ([@B1]) or DC-CIK strategy ([@B65]) and usage of checkpoint inhibitors (anti-PD-1, anti-CTLA4, etc.) ([@B54]) as well as tumor vaccines ([@B29]) bring about great benefits for certain populations of patients. To further improve the selectivity, biomarker-discovery-based monoclonal antibody development and finely designed nanoparticle carriers are applied. Nonetheless, these measures are not enough to win the battle against tumors. The side effect, off-target effect, and loss of effect are prevalent phenomena among present therapeutic protocols. Thus, it is of importance to pursue additional methods and bioactive anti-tumor compounds.

Glucomannan is a family of polysaccharide widely existing in higher plants and microorganisms. The backbone structure is β-(1→4) glycoside bond linked D-mannose and D-glucose in a ratio of 1.6:1, while it is only lightly branched through β-(1→6) glucosyl moieties ([@B56]). The molecular weight ranges from 200,000 to 2,000,000 Daltons, which varies with origin, method of processing, and storage time. In general, glucomannan has favorable characteristics of water solubility and extremely low toxicity ([@B23]; [@B37]), which make it a fantastic bio-compatible compound. Actually, Konjac glucomannan, the well-known member of the glucomannan family, was first documented as a traditional Chinese herb about 2000 years ago ([@B15]). Since then, it has been used to treat conditions such as asthma, cough, hernia, breast pain, burns, and hematological and skin diseases ([@B15]). Nowadays, it mainly serves either as a dietary supplement aiding in weight loss, diabetes, arterial sclerosis, and constipation, or as an emulsifier and thickener in food processing ([@B10]; [@B58]), which corroborates the old theory of "homology of medicine and food." In fact, many natural polysaccharides that show potent anti-tumor activity ([@B30]; [@B60]; [@B64]; [@B17]) derive from edible herbs, such as *Lentinus*, *Cordyceps*, *Ganoderma lucidum*, and *Hericium*, which themselves are also common cuisine ingredients. Recently, glucomannan extracted from *Amorphophallus konjac* ([@B10]), *Bletilla striata* ([@B63]), *Lentinus edodes* ([@B20]), *Aloe vera* ([@B47]; [@B25]; [@B33]; [@B26]; [@B43]), and *Candida utilis* ([@B32]) were demonstrated to have similar effect. Moreover, according to the studies reviewed in the present research, glucomannan, mainly from these species, not only is an anti-cancer drug by itself but also works as a targeted carrier that is compatible with various bioactive compounds.

Glucomannan Directly Interferes With Intrinsic Tumor Cells Biological Processes {#s2}
===============================================================================

Glucomannan Impairs Tumor Cells' Survival and Metastasis {#s2_1}
--------------------------------------------------------

Given that tumor cells are apoptosis resistant, drugs aimed to promote apoptosis are widely used in cancer therapy ([@B23]). Initially, studies unveiled the therapeutic effect of extract from *A. konjac* (AKe) on various cancers, such as colon carcinoma ([@B3]; [@B4]), gastric cancer ([@B10]), hepatoma ([@B5]), and breast cancer ([@B58]; [@B57]). Chen et al. found that AKe could inhibit the growth of *in vitro* cultured gastric cancer cell lines SGC-7901 and AGS ([@B10]). On the molecular level, the expression of inhibitors of apoptosis protein (IAP) family member survivin and the pro-survival gene *BCL2* decreased, while the pro-apoptosis protein BAX and caspase-9 increased ([@B10]) ([**Figure 1**](#f1){ref-type="fig"}). AKe also displayed similar therapeutic effect on human liver cancer cell line and the human triple-negative breast cancer (TNBC) cells ([@B5]; [@B58]). By blocking the transition from G0/G1 to G2/M phase and decreasing the expression of the proliferative marker proliferative cell nuclear antigen (PCNA), AKe promotes cell cycle arrest and inhibits cell division ([@B3]; [@B10]) ([**Figure 1**](#f1){ref-type="fig"}). The elevated activity of tumor cell apoptosis is always accompanied by decreased cell proliferation, which stems from the shared down-regulated PI3K/AKT signaling pathway ([@B19]; [@B21]). Since Konjac glucomannan was identified as the major bioactive component of the *A. konjac* ([@B10]), not surprisingly, Sawai S. and his colleagues found that Konjac-glucomannan-treated HepG2 hepatic carcinoma cells displayed a significant reduction of growth, which resembles the phenotype of AKe-treated tumor cells ([@B49]).

![Direct effects on tumor cell biological processes. **(A)** Glucomannan promotes tumor cell apoptosis through the up-regulation of pro-apoptotic proteins BAX and Caspase-9 and the down-regulation of anti-apoptotic genes like Survivin and BCL2. **(B)** Glucomannan inhibits tumor cell proliferation through the blockade of G0/G1 to G2/M phase transition and decreases the expression of PCNA. **(C)** Glucomannan hinders tumor cell metastasis by decreasing CCR7 and CXCR4 expression and increasing E-cadherin level. **(D)** Glucomannan promotes autophagy and reduces ROS production in tumor cells, thus leading to the alleviation of DNA damage and subsequent mutation events.](fphar-10-00930-g001){#f1}

Indeed, the PI3K/AKT/mTOR pathway is frequently hyper-activated in tumor cells and also plays an important role in cancer metastasis ([@B21]). AKe was found to inhibit PI3K signaling pathway and thwart MDA-MB231 breast cancer cell metastasis to lung in a xenograft model ([@B58]). The chemokine receptors and adhesion molecules are strongly linked to tumor recurrence and metastasis. AKe was reported to significantly increase E-cadherin expression and reduce CCR7 and CXCR4 level, which are required for tumor migration ([@B58]) ([**Figure 1**](#f1){ref-type="fig"}). Moreover, the glucomannan extracted from the *C. utilis* preferentially inhibited the Lewis lung carcinoma (3LL) pulmonary metastases in a time-dependent manner, wherein an optimal dosage of glucomannan on early stage exhibits the optimal suppressive effect ([@B32]).

Collectively, these data outline the intrinsic impacts of glucomannan on tumor cell apoptosis, proliferation, and metastatic activity, which are the essential basis for its anti-tumor function. To a large extent, such effects are attributed to glucomannan-mediated inhibition of the PI3K/AKT signaling pathway. As a result, increased ratio of pro-apoptotic to anti-apoptotic gene expression undermines the immortality of tumor cells, while the reduced level of CCR7 and CXCR4 compromises their migratory capability.

Glucomannan Enhances Anti-Oxidative Activity and Induces Autophagy in Tumor Cells {#s2_2}
---------------------------------------------------------------------------------

Another glucomannan-mediated anti-cancer effect could be ascribed to its role as an antioxidant inducer ([@B38]; [@B3]; [@B5]; [@B59]). An earlier study confirmed that glucomannan isolated from *C. utilis* exerts anti-mutagenic function in a mouse model of cyclophosphamide-induced mutagenicity, which may result from the decreased ROS level ([@B14]). Miadoková et al. further concluded that glucomannan from *C. utilis* cell wall exerts the anti-oxidative activity through iron chelation and scavenging of hydroxyl radicals in mouse leukemia cell ([@B38]). In line with the above observation, glucomannan or AKe was demonstrated to enhance the expression of antioxidant enzymes in 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis and *N*-nitrosodiethylamine-induced hepatocellular carcinoma in rats ([@B3]; [@B6]). Besides, Konjac glucomannan was able to ameliorate AOM-induced genotoxicity *via* alleviating the DNA damage process initiated by accumulated ROS ([@B59]) ([**Figure 1**](#f1){ref-type="fig"}).

Alternatively, in the gastric cancer cell lines SGC-7901 and AGS, investigators found that AKe treatment markedly increased the expression of LC3-II, which is a marker of the mature autophagosome and indicates high level of autophagy ([@B10]). Increased cell autophagy plays a protective role in early tumor development, with the possible mechanisms of autophagy-related stress elimination and even autophagy-induced cell death. Nassour et al. found that autophagy is an important cellular protective process to induce cell death during replicative crisis and impaired autophagy is required for initiation of tumorigenesis ([@B41]). Though the AKT/mTOR pathway may be related to the activation of the autophagic process ([@B8]), there is no definite evidence showing the existence of the glucomannan-AKT/mTOR-autophagy axis in the tumor cells.

Glucomannan Indirectly Affects Tumor Development {#s3}
================================================

Glucomannan Promotes Extrinsic Environment Disfavoring Tumorigenesis {#s3_1}
--------------------------------------------------------------------

Glucomannan displays a beneficial effect for constipation and promotes intestinal peristalsis. As a dietary water-absorbing fiber, it has also been demonstrated to reduce the production of carcinogens from the gut ([@B40]; [@B55]; [@B56]; [@B13]). Due to its hydrolytic ability of turning substances into carcinogens, β-glucuronidase is identified as a lysosomal enzyme involved in the process of tumor development and metastasis ([@B31]). Another protein peptide hydrolase, mucinase, is able to hydrolyze the mucin layer of the gut lumen and make the enterocytes to be in direct contact with colon carcinogens ([@B39]). According to Dr. Wu's research, the incorporation of Konjac glucomannan in high-fat fiber-free diet in rats decreased the activity of β-glucuronidase and mucinase by 71% and 68%, respectively ([@B55]) ([**Figure 2**](#f2){ref-type="fig"}).

![Indirect effects through extrinsic environment. Inhibition of the activity of mucinase and β-glucuronidase is achieved through glucomannan or glucomannan-induced colonization of probiotics, which results in reduced carcinogens and increased SCFAs content in the gut lumen. Altogether, the tumor development is suppressed.](fphar-10-00930-g002){#f2}

Studies proved that bile acid is in close relationship with the carcinogenesis process ([@B40]). It could promote gastrointestinal (GI) inflammation ([@B27]) and change the composition of normal gut microbiota, by means of which bile acid becomes a risk factor during tumor formation ([@B27]). Administration of Konjac glucomannan was found to increase the fecal output of total bile acids in rats ([@B24]; [@B55]). What's more, Konjac glucomannan significantly decreases secondary bile acid level in human subjects ([@B56]). Therefore, the reduction of bile acids would be another functional aspect of glucomannan supplementation.

On the other hand, the probiotics, mainly *lactobacilli* and *bifidobacteria*, are indicated for their anti-colorectal cancer function through binding to the mutagens, inhibiting the activity of β-glucuronidase, and reducing the level of carcinogenic secondary bile acid ([@B56]; [@B13]). In various studies, glucomannan is shown to enhance the content of probiotics and its metabolic products, short-chain fatty acids (SCFAs), in feces ([@B40]; [@B24]; [@B61]; [@B55]; [@B56]; [@B13]; [@B59]; [@B43]). SCFAs promote the functionality of normal intestinal epithelium and the gut integrity ([@B13]); also, they stimulate cell differentiation program and induce apoptosis of transformed cells ([@B32]; [@B61]; [@B13]). Taken together, these results suggest that glucomannan could indirectly promote an environment that is unfavorable for cancer development, at least in the gastroenterological system ([**Figure 2**](#f2){ref-type="fig"}).

Glucomannan Serves as a Targeted Carrier for Anti-Cancer Drug Delivery {#s3_2}
----------------------------------------------------------------------

A specific drug delivery system is necessary to enhance the efficacy of existing chemotherapeutic drugs and to reduce their side effect. Glucomannan exhibits very low toxicity, modifiability, and the absence of immunogenicity ([@B63]). These outstanding characteristics make it an ideal drug carrier.

Amphiphilic aliphatic amines grafted Konjac glucomannan micelle (Konjac glucomannan-g-AHs), a modified Konjac glucomannan, is added with a pH-sensitive Schiff's base. With improved stability, solubility, and cytotoxicity, the Konjac-glucomannan-based micelles are able to protect the curcumin from degradation and deliver it into the tumor site through endocytosis-mediated transmembrane transport ([@B37]). Furthermore, glucomannan synergizes with other bioactive compounds to exert anti-tumor function. Combined with teniposide, they display enhanced cytotoxic and cytostatic effect on mouse leukemia cells ([@B38]) ([**Figure 3**](#f3){ref-type="fig"}). In addition, the Konjac glucomannan/sodium alginate/graphene oxide (Konjac glucomannan/SA/GO) complex could effectively control the release of anti-cancer drug 5-FU in a local tumor site, thus reducing the systematic side effect ([@B53]; [@B62]). Liu et al. designed a novel glucomannan-containing, aromatic azo agent bis(methacryloyl-amino)-azobenzene cross-linked hydrogel, which can release peptide drugs at the colon site in a pH-dependent or enzymatic degradation mode ([@B34]). Chitosan (CS)-coated microsphere, generated on the basis of oxidized Konjac glucomannan, makes another promising intestine-specific drug delivery approach for the treatment of bowel diseases, according to Shi's study ([@B50]). In brief, glucomannan is compatible with many other bioactive compounds and the conjugated macromolecular complexes could be easily taken by tumor cells, thus improving the therapeutic efficacy of existing anti-cancer chemicals.

![Indirect effects through tumor immune microenvironment. Glucomannan can serve as a drug carrier of anti-tumor drugs such as 5-FU and teniposide towards tumor cells or deliver apoptosis-inducing drug alendronate to TAMs through binding to mannose receptor (MR). Alternatively, glucomannan can directly bind to TLR4 receptor expressed by TAMs and leads to the secretion of IL-6, etc. In brief, administration of glucomannan reshapes the tumor immune microenvironment by increasing anti-tumor cytokines TNFα and IFN-γ and decreasing tolerance-related cytokines like IL-10.](fphar-10-00930-g003){#f3}

The Effect of Glucomannan on a Tumor Immune Microenvironment {#s3_3}
------------------------------------------------------------

Progression of tumor into malignant stage is closely associated with a compromised immune surveillance function, wherein tumor-associated macrophages (TAMs) are predominantly involved ([@B63]). Actually, glucomannan from Porang was demonstrated to activate macrophages through Toll-like receptor 4 (TLR4), increasing the production of interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) and promoting its phagocytic capability in primary macrophages ([@B22]) ([**Figure 3**](#f3){ref-type="fig"}). On the other hand, ubiquitous surface expression of glucose and mannose receptors makes TAMs possible targets for polysaccharides with anti-tumor activity ([@B14]; [@B18]; [@B63]). Although no specific study indicates that the glucomannan binding to the sugar receptor has direct influence on macrophage, studies emphasize the intermediary role of glucomannan as a TAM-targeting molecule. Glucomannan isolated from *B. striata* (BSP) shows nucleic acid binding affinity after modification by *N*,*N*'-carbonyl di-imidazole (CDI)/ethylene diamine ([@B63]). The anti-sense nucleotides such as oligo-deoxynucleotide and small interference RNA (siRNA) could be delivered by the modified glucomannan *via* the recognition of macrophage surface receptors, which mediates the manipulation of TAM-related gene expression level ([@B18]). A study shows that glucomannan helps to selectively deliver alendronate to tumor-resident macrophages, thus leading to the apoptosis and depletion of TAMs ([@B63]) ([**Figure 3**](#f3){ref-type="fig"}). Also, the bisphosphonate glucomannan conjugate, consisting of poly-ethylene glycol (PEG), poly(lactic-co-glycolic acid) (PLGA), and a peptide that can be cleaved by matrix metalloproteases (MMPs), could be efficiently released to tumor sites and reduce the viability of TAMs.

Moreover, glucomannan was demonstrated to enhance the immune function both *in vivo* and *in vitro* ([@B63]). Interleukin-10 (IL-10) is known as an immunosuppressive cytokine that is enriched in tumors to counteract the killing activity of cytotoxic T lymphocytes (CTLs) ([@B46]). Glucomannan could re-energize the immune system to attack the tumor cells by decreasing IL-10 level and promoting the production of IFN-γ in tumor sites ([@B51]; [@B63]). Similarly, the acidolysis-oxidized Konjac glucomannan up-regulates the expression of cytokines like TNFα, interleukin-1β (IL-1β), and IL-6, which collectively bolster the anti-tumor immune response ([@B52]; [@B11]) ([**Figure 3**](#f3){ref-type="fig"}). However, it is important to note that glucomannan has also been suggested to possess an anti-inflammatory effect ([@B42]; [@B56]). Onishi N et al. indicated that pulverized konjac glucomannan suppressed the skin inflammatory immune response in NC/Nga mice evidenced by decrease of substance P, IL-10, IL-4, and TNFα ([@B42]). Thus, whether the immune regulatory function of glucomannan is bidirectional or the immune motivating role is specific in local tumor environment remains to be determined by future studies.

Discussion {#s4}
==========

As a straight-chain polymer with few branches, glucomannan was first appreciated for its role in gastroenterological disorders and metabolic diseases. Much similar to other polysaccharide extracts from traditional Chinese herbs, recently, the potential of glucomannan involved in anti-cancer therapy is being revealed. Accumulating evidence suggests that glucomannan exhibits broad but specific anti-tumor effect, when distinct cancer types are concerned ([**Table 1**](#T1){ref-type="table"}).

###### 

The anti-tumor mechanism of glucomannan in different cancer types.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source of GM                                                                        Cancer type                        Model                                                       Mechanism               
  ----------------------------------------------------------------------------------- ---------------------------------- ----------------------------------------------------------- ----------------------- -----------------------------------------------------------------------------------
  \                                                                                   Breast cancer ([@B58]; [@B57])     *In vitro*                                                  MDA-MB-231              Induce cell cycle arrest
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  \                                                                                                                                                                                                          
  *Amorphophallus konjac*                                                                                                                                                                                    

  MDA-MB-231BO                                                                        Inhibit migration and invasion                                                                                         

  *In vivo*                                                                           Mice                               Regulation of the chromosomal and centrosomal instability                           

  Hepatoma ([@B3]; [@B6]; [@B5]; [@B49])                                              *In vitro*                         PLC/PRF/5                                                   Anti-proliferation      

  HepG2                                                                               Increase apoptosis                                                                                                     

  *In vivo*                                                                           Rat                                Anti-oxidative stress                                                               

  Decrease cell viability                                                                                                                                                                                    

  Promote the production of propionate                                                                                                                                                                       

                                                                                      *In vitro*                         SGC-7901                                                    Increase apoptosis      

  Gastric cancer ([@B10])                                                             AGS                                Induce cell cycle arrest                                                            

  *In vivo*                                                                           Human                              Promote autophagy                                                                   

  Colon carcinoma ([@B55]; [@B3]; [@B3]; [@B4]; [@B59])                               *In vitro*                         HCT-15                                                      Induce apoptosis        

  Anti-proliferation                                                                                                                                                                                         

  *In vivo*                                                                           Rat                                Anti-oxidative stress                                                               

  Reduce β-glucuronidase and mucinase activities                                                                                                                                                             

  Promote the growth of *bifidobacteria* and *lactobacilli* and production of SCFAs                                                                                                                          

  Lung cancer                                                                         *In vivo*                          Mice                                                        ---                     

  *Candida utilis*                                                                    Lung cancer ([@B32])               *In vivo*                                                   Mice                    Inhibit migration and invasion

  Leukemia ([@B38])                                                                   *In vitro*                         P388D1                                                      Anti-oxidative stress   

  *Lentinus edodes*                                                                   Ehrlich ascites tumor              *In vivo*                                                   Mice                    Induce expression of interferons

  Sarcoma S180-bearing ([@B20])                                                                                                                                                                              

  *Bletilla striata*                                                                  Sarcoma S180-bearing ([@B63])      *In vivo*                                                   Mice                    Targeted depletion of TAMs

  *Aloe vera*                                                                         Colon carcinoma ([@B26]; [@B43])   *In vitro*                                                  HT29                    Promote the growth of *bifidobacteria* and *lactobacilli* and production of SCFAs

  *In vivo*                                                                           Mice                               Induce cell cycle arrest                                                            

  Leukemia ([@B47])                                                                   *In vitro*                         C1498                                                       Anti-proliferation      

  Ehrlich ascites tumor                                                               *In vivo*                          Mice                                                        Activate macrophages    

  Sarcoma 180-bearing ([@B25]; [@B33])                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCFAs, short-chain fatty acids; TAMs, tumor-associated macrophages.

Mechanistically, glucomannan has direct impact on tumor cell survival and metastasis by blocking the PI3K/AKT signaling pathway ([@B19]; [@B21]). After glucomannan treatment, cells show increased apoptosis along with decreased proliferation capacity. Meanwhile, the expression of chemokine receptors (CCR7 and CXCR4) is reduced, which abrogates the migratory ability of the tumor cells ([@B58]). Uncontrolled cellular stress is pivotal in the early stage of tumorigenesis. Notably, hyperactive tumor metabolism leads to elevated ROS level and subsequent oxidative stress, which would cause genotoxicity and accumulation of mutations required for tumor development ([@B59]). Autophagy is a stress response characterized by degradation of self-components and the formation of autophagosomes. During early-stage tumor development, autophagy exerts a tumor-suppressive function through the clearance of stress-induced organelle damage. Glucomannan displays a protective effect by promoting the expression of genes associated with ROS scavenging and autophagy induction ([@B10]). Though the underlying mechanism remains obscure, it is plausible to reason that the PI3K/AKT signaling pathway may also be critically involved in such stress responses. Studies show that inhibition of the PI3K/AKT pathway limits the glycolytic process and deprives tumor cells of energy supply ([@B9]; [@B16]), which could explain the reduction of ROS content ([@B44]; [@B66]) and the elevation of cell autophagy level ([@B28]; [@B12]; [@B35]). Altogether, glucomannan ameliorates cellular stress and prevents the tumorigenesis process.

Other than the direct interference of tumor cell biology, glucomannan also functions in an indirect manner. Glucomannan administration reduces carcinogen production in gut lumen and promotes probiotics and SCFA generation, which suppresses GI inflammation-related carcinogenesis ([@B56]). On the other hand, due to its excellent bio-compatibility, glucomannan can work as a targeted delivery platform to enhance the efficiency of traditional drugs like curcumin ([@B37]), teniposide ([@B38]), and 5-FU ([@B53]). Anergic immune microenvironment is an important culprit in the process of tumor growth and evasion; thus, current therapies like checkpoint inhibitors are designed to motivate and re-energize the attacking ability of effector immune cells. Strikingly, glucomannan could alter the cytokine profile in the tumor vicinity and thus in support of CTL-mediated cytotoxic effect. TAMs, tumor resident macrophages that contribute to the induction of a tolerant immune milieu, express receptors for various polysaccharide molecules. Glucomannan could increase macrophage phagocytic activity and cytokine secretion, such as TNFα and IL-6, *via* binding to TLR4 ([@B22]). It also facilitates the function of other compounds like siRNA ([@B18]) and alendronate ([@B63]) to induce TAM apoptosis. All in all, further studies are needed to understand the details of how glucomannan impacts the immune system.

Cancer, the primary killer in modern society, is a complicated and systematic disease. The ultimate goal in cancer therapy is to completely eradicate tumor cells and reach the criteria of clinical cure without disease recurrence. It is a challenging task, considering the presence of cancer stem cells, intra-tumoral heterogeneity, and the formidable adaptability of tumor cells. While in pursuit of such purpose, it is also important to render patients live in "harmony" with their tumors, which means to maintain the high quality of life amid the effort to stop tumor from deterioration. According to a report published in *JAMA Oncology* in 2019, 1/3 of cancer patients would seek for help from alternative medicines ([@B48]). Nature holds the key to cancer management, and ethnopharmacological herbs may be one of the answers that nature provides. Therefore, the identification, synthesization, and modification of additional bioactive anti-tumor compounds like glucomannan from natural ethnopharmacological herbs would greatly benefit the process of anti-tumor therapy and contribute to the improvement of human health.
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